Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Operating Income (2016 - 2025)

Regenxbio (RGNX) has 12 years of Operating Income data on record, last reported at -$57.6 million in Q4 2025.

  • For Q4 2025, Operating Income fell 12.2% year-over-year to -$57.6 million; the TTM value through Dec 2025 reached -$161.2 million, up 30.92%, while the annual FY2025 figure was -$161.2 million, 30.92% up from the prior year.
  • Operating Income reached -$57.6 million in Q4 2025 per RGNX's latest filing, down from -$52.4 million in the prior quarter.
  • Across five years, Operating Income topped out at $313.6 million in Q4 2021 and bottomed at -$73.1 million in Q2 2023.
  • Average Operating Income over 5 years is -$27.6 million, with a median of -$57.7 million recorded in 2022.
  • The widest YoY moves for Operating Income: up 623.92% in 2021, down 511.07% in 2021.
  • A 5-year view of Operating Income shows it stood at $313.6 million in 2021, then crashed by 118.42% to -$57.8 million in 2022, then surged by 357.67% to $148.9 million in 2023, then crashed by 134.51% to -$51.4 million in 2024, then dropped by 12.2% to -$57.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were -$57.6 million in Q4 2025, -$52.4 million in Q3 2025, and -$63.3 million in Q2 2025.